Topical Oxybutynin (Gelnique) for Overactive Bladder
The FDA has approved the marketing of a 10% topical gel formulation of the muscarinic receptor antagonist oxybutynin chloride (Gelnique - Watson) for treatment of overactive bladder. Oxybutynin is also available for this indication as oral tablets, an oral syrup and a transdermal patch....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Topical Oxybutynin (Gelnique) for Overactive Bladder
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1331
Article Code: 1331b
Date: February 8, 2010
Volume: 52
Pages: 10-11
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1331
Article Code: 1331b
Date: February 8, 2010
Volume: 52
Pages: 10-11
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)